Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 255 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asymptomatic Condition Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Lubiprostone and Mucus Secretion in Patients With Chronic Constipation

NCT01447849
View directory record Official record
Conditions
Constipation
Interventions
lubiprostone, placebo
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 30, 2026, 4:11 AM EDT
Completed No phase listed Observational

A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test

NCT05331976
View directory record Official record
Conditions
COVID-19, Asymptomatic COVID-19
Interventions
Proof Lab Test System
Diagnostic Test
Lead sponsor
Proof Diagnostics
Industry
Eligibility
2 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Spring Hill, Florida • Statesville, North Carolina • Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Placebo, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

NCT00002357
View directory record Official record
Conditions
HIV Infections
Interventions
HBY 097, Zidovudine
Drug
Lead sponsor
Hoechst Marion Roussel
Industry
Eligibility
13 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

NCT01884688
View directory record Official record
Conditions
Asymptomatic Multiple Myeloma
Interventions
ENK Cell Infusion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 30, 2026, 4:11 AM EDT
Recruiting Phase 1 Interventional

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

NCT03219450
View directory record Official record
Conditions
Lymphocytic Leukemia
Interventions
NeoVax, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 4:11 AM EDT
Terminated Not applicable Interventional Results available

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

NCT00106938
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions
Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical)
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients

NCT00781339
View directory record Official record
Conditions
Asymptomatic Bacteriuria
Interventions
sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Not applicable Interventional Results available

Carotid Revascularization Endarterectomy Versus Stenting Trial

NCT00004732
View directory record Official record
Conditions
Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
Interventions
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
106
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 30, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional

Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma

NCT00216151
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Zoledronic Acid
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Elkhart, Indiana • Evansville, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Trial of Clinical Decision Making in Asymptomatic Carotid Stenosis

NCT01315288
View directory record Official record
Conditions
Carotid Stenosis
Interventions
One of 6 video presentation by one of 4 presenters
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 30, 2026, 4:11 AM EDT
Completed No phase listed Observational Results available

Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates

NCT01353196
View directory record Official record
Conditions
Cognitive Manifestations
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Not applicable Interventional Results available

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography

NCT02306265
View directory record Official record
Conditions
Breast Cancer, Tumors, Breast, Cancer Screening
Interventions
FFDM, DBT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Royal Oak, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 30, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

NCT00002106
View directory record Official record
Conditions
HIV Infections
Interventions
Ranitidine hydrochloride
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Sherman Oaks, California • Coral Gables, Florida • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:11 AM EDT
Terminated Not applicable Interventional

A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3

NCT00001064
View directory record Official record
Conditions
HIV Infections
Interventions
Allogenic Dendritic Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 30, 2026, 4:11 AM EDT
Completed No phase listed Observational

Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

NCT00050284
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 30, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol

NCT01697397
View directory record Official record
Conditions
Gastrointestinal Diseases
Interventions
Recording of Myoelectric Signals
Device
Lead sponsor
G-Tech Corporation
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Watchful Waiting Versus Open Tension-free Repair of Inguinal Hernia in Asymptomatic or Minimally Symptomatic Men

NCT00263250
View directory record Official record
Conditions
Inguinal Hernia
Interventions
watchful waiting or tension-free hernia repair
Procedure
Lead sponsor
Creighton University
Other
Eligibility
18 Years and older · Male only
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Oct 30, 2026, 4:11 AM EDT
Recruiting Not applicable Interventional

Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations

NCT07539597
View directory record Official record
Conditions
Asymptomatic Hypertension
Interventions
Community Health Worker engagement
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

NCT04348747
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Tampa, Florida • Buffalo, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 3 Interventional

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00027859
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, ketoconazole, therapeutic hydrocortisone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
98
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 30, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00000664
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 30, 2026, 4:11 AM EDT